Loading stock data…
WGS
$39.61-1.16 (-2.85%)
After Hours$39.06-0.55 (-1.39%)· Last close May 11
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeneDx Holdings Corp. in the Healthcare sector is trading at $39.61. The stock is currently near its 52-week low of $32.21, remaining 63.3% below its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why WGS maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$39.61
Potential Upside
5%
Whystock Fair Value$41.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$77.00+94.4%
Range$50.00 – $100.00
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-90.99%
Volume
Today's trading volume
1.82M
Recent News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
One of these stocks plummeted 49% on Tuesday.
The 'Alarming' Results That Caused GeneDx Stock To Plummet 49%
GeneDx stock crashed Tuesday on what one analyst called its "alarming" first-quarter sales miss, leading to a guidance cut for the year.
Why GeneDX Stock Is Plummeting Today
GeneDX's latest quarterly report arrived with a lot of bad news for investors.
Does GeneDx’s Guidance Cut And Core Shift Reshape The Bull Case For GeneDx Holdings (WGS)?
GeneDx Holdings Corp. has already reported first-quarter 2026 results, with revenue rising to US$102.25 million while net loss widened to US$63.32 million, and management cut full-year 2026 revenue guidance after missing expectations on both revenue and earnings. Behind the headline loss, the quarter showed 34% growth in exome and genome test volumes alongside a US$25 million cost-cut plan and a sharper focus on core diagnostics over underperforming non-core lines. Next, we examine how this...
GeneDx Holdings Corp. Q1 2026 Earnings Call Summary
Moby summary of GeneDx Holdings Corp.'s Q1 2026 earnings call